Skip to content
10-Q

Quarterly Report

Cartesian Therapeutics, Inc. RNAC

0001453687-26-000082

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 23, 2026 29.38M sh
Shares Diluted Q1 2026 · Mar 31, 2026 26.86M sh
Shares Diluted Q1 2026 · Mar 31, 2025 25.9M sh
Capex Q1 2026 · Mar 31, 2026 $27K
Capex Q1 2026 · Mar 31, 2025 $1.08M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$22.14M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$23.11M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $118.64M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $125.14M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $180.43M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$148.12M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$126.24M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$21.79M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$6.8M
Current Liabilities Q1 2026 · Mar 31, 2026 $15.95M
Current Liabilities Q1 2026 · Dec 31, 2025 $14.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $436.51M
Total Liabilities Q1 2026 · Dec 31, 2025 $422.65M
Current Assets Q1 2026 · Mar 31, 2026 $122.04M
Current Assets Q1 2026 · Dec 31, 2025 $129.28M
Total Assets Q1 2026 · Mar 31, 2026 $288.39M
Total Assets Q1 2026 · Dec 31, 2025 $296.41M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.46
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.68
Eps Basic Q1 2026 · Mar 31, 2026 −$1.46
Eps Basic Q1 2026 · Mar 31, 2025 −$0.68
Sga Expense Q1 2026 · Mar 31, 2026 $7.11M
Sga Expense Q1 2026 · Mar 31, 2025 $8.32M
Rd Expense Q1 2026 · Mar 31, 2026 $19.46M
Rd Expense Q1 2026 · Mar 31, 2025 $14.67M
Net Income Q1 2026 · Mar 31, 2026 −$39.18M
Net Income Q1 2026 · Mar 31, 2025 −$17.71M
Operating Income Q1 2026 · Mar 31, 2026 −$26.5M
Operating Income Q1 2026 · Mar 31, 2025 −$21.89M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $400K